[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editorial
April 2010

Interferon Neutralizing Antibodies in Multiple SclerosisA New Perspective

Author Affiliations

Author Affiliation: Multiple Sclerosis Center at Texas Neurology and Baylor Institute for Immunology Research, Dallas.

Arch Neurol. 2010;67(4):386-387. doi:10.1001/archneurol.2010.31

The significance of antibodies induced by therapeutically administered formulations of recombinant human interferon β (IFN-β) in multiple sclerosis (MS) has been a controversial topic since it was first reported in association with IFN-β-1b in 1993.1 Indeed, all current formulations of IFN-β are immunogenic (but in varying degrees) such that high titers of induced IFN-β neutralizing antibodies (NAb) do in fact neutralize in vitro IFN-β bioactivity. With regard to all currently available IFN-β—despite early, inconclusive, and often opposing studies—review of the world literature on this topic has allowed task forces of the European Federation of Neurological Societies2 and the American Academy of Neurology3 to agree on several important conclusions:

First Page Preview View Large
First page PDF preview
First page PDF preview
×